Targeted RNA Editing
Technology Platforms

RecoRNA(Guangzhou) Biotechnology Co., Ltd, is a pioneering biotechnology company focused on the development of RNA-targeted editing technologies to tackle diseases that currently lack effective conventional treatments. The company is committed to addressing the unmet clinical needs in genetic diseases, neurological disorders, chronic diseases, and other therapeutic areas, and is dedicated to advancing the development of precision medicine through cutting-edge technologies.

RecoRNA possesses RNA therapy platform, which includes a world-leading RNA single-base editing design platform based on the world’s largest ADAR substrate editing library, a RNA fragment excising tool,and the AI-driven ATOMIC screening platform.These breakthrough innovations provide strong support and assurance for the company's research and development of novel drugs. Through these top-notch technologies, the company is able to overcome the limitations of traditional small-molecule and biologic drugs, and to address key therapeutic challenges such as frameshift mutation diseases, single-point mutation genetic diseases, metabolic diseases and Immuno-oncology diseases. At the same time, our technical strategies ensure to avoid the irreversible off-target safety risks associated with DNA-level gene editing therapies.

Xu Xin (Hong Kong) Biotechnology Co., Ltd.,a wholly-owned subsidiary of RecoRNA(Guangzhou) Biotechnology Co., Ltd, at the Hong Kong Science Park. It has built an AI technology platform that overcomes the bottleneck of traditional R&D, and accelerate the entire process from target discovery, lead optimization and candidate selection.